SEL24/MEN1703 Demonstrates Early Efficacy, Tolerability in R/R AML With IDH1/2 Mutations
September 1st 2022The first-in-class dual PIM/FLT3 kinase inhibitor, SEL24/MEN1703, showcased encouraging efficacy and a tolerable safety profile in patients with acute myeloid leukemia whose tumors harbor a IDH1/2 mutation.
Read More
Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma
September 1st 2022Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.
Read More
Continued Emergence of Targeted Therapies Reinforces Need for Frequent Genetic Testing in NSCLC
August 25th 2022Although the efficacy of targeted agents and outcomes for patients with genetic mutations can vary, the availability of these treatments adds to the need for genetic testing across all patients with non–small cell lung cancer.
Read More
Acalabrutinib With or Without Obinutuzumab Maintains Long-Term Survival Benefit in Untreated CLL
August 24th 2022Jeff P. Sharman, MD, discusses the meaning of the long-term follow-up data from ELEVATE-TN, the efficacy of acalabrutinib regimens in patients with treatment-naïve chronic lymphocytic leukemia with deletion 17p or TP53 mutations, and factors to consider when adding obinutuzumab to acalabrutinib.
Read More
Relma-cel Demonstrates Durable Activity in Relapsed/Refractory LBCL
August 22nd 2022Relmacabtagene autoleucel elicited durable responses and a high overall survival rate in Chinese patients with relapsed/refractory large B-cell lymphoma, according to 2-year follow-up data from the phase 2 RELIANCE trial.
Read More
CART-ddBCMA Generates Deep Responses in Relapsed/Refractory Multiple Myeloma
August 19th 2022Matthew J. Frigault, MD, discusses the findings from a phase 1 trial investigating the safety and efficacy of CART-ddBCMA in patients with multiple myeloma in whom all previous lines of treatment had failed and shares additional research opportunities for the CAR T-cell therapy.
Read More
CCNE1 Amplifications Tied to Racial Disparities in Serous Endometrial Cancer Outcomes
August 18th 2022Julian Schink, MD, discusses a study evaluating racial differences in the mutational landscape of serous endometrial cancer, underscores the need for appropriate genomic testing and treatment for Black women with the disease, and explains the importance of racial representation across clinical trials.
Read More
Trastuzumab Deruxtecan Shakes Up Treatment Possibilities for HER2-Low Metastatic Breast Cancer
August 17th 2022Katherine Tkaczuk, MD, discusses practice-changing data across breast cancer subtypes that were discussed at the 2022 ASCO Annual Meeting, including data from DESTINY-Breast04 and the phase 3 PALOMA-2 trial, plus the utilization of CDK4/6 inhibitors and PARP inhibitors for select patients with breast cancer.
Read More
Raul Cordoba, MD, PhD, discussed the efficacy and safety findings from cohort 4 of the EPCORE NHL-2 trial, the benefits observed with epcoritamab monotherapy in patients who did not proceed to transplant, and what the addition of epcoritamab to R-DHAX/C could mean for patients with relapsed/refractory DLBCL.
Read More
Belzutifan Generates Promising Responses and Safety in Advanced Stage Clear Cell RCC
August 15th 2022Eric Jonasch, MD, discusses the efficacy and safety of belzutifan observed in the LITESPARK-001 trial for patients with advanced clear cell RCC and the next steps for investigating belzutifan in this patient population.
Read More
Immunotherapy Combination Selection Is Driven by PD-L1 in Gastroesophageal Cancer
August 11th 2022Andrew H. Ko, MD, discusses the multitude of treatment options for patients with gastroesophageal cancer, emerging combinations in hepatocellular carcinoma, and how HER2 expression can drive therapy decisions in colorectal cancer.
Read More
Azacitidine/Quizartinib Combo Showcases Early Activity in MDS, MDS/MPN With FLT3 or CBL Mutations
August 5th 2022The combination of azacitidine and quizartinib produced preliminary responses in patients with myelodysplastic syndrome and myelodysplastic syndrome/myeloproliferative neoplasms whose tumors harbored FLT3 or CBL mutations, according to data from a phase 1/2 trial (NCT04493138).
Read More
Ropeginterferon Alfa-2b Proves to be Efficacious, Safe in Japanese Patients with Polycythemia Vera
August 2nd 2022Ropeginterferon alfa-2b produced durable complete hematologic responses without phlebotomy and showcased a consistent safety profile in Japanese patients with polycythemia vera, according to findings from a phase 2 study (NCT04182100) presented during the 2022 EHA Congress.
Read More
Glutaminase Inhibition Represents Novel Treatment Strategy in NFE2L2- and KEAP1-Mutated NSCLC
July 30th 2022Jonathan Wesley Riess, MD, MS, discusses a phase 1 trial examining the combination of sapanisertib and telaglenastat, and explains why glutaminase inhibition is being investigated as a novel way to treat select patients with non–small cell lung cancer.
Read More
Oral SERDs Could Fulfill Unmet Need in ESR1-Mutant, ER-Positive Breast Cancer
July 29th 2022Aditya Bardia, MD, MPH, discusses recent and ongoing trials evaluating oral SERDs in estrogen receptor–positive breast cancer, the effect of ESR1 mutations on treatment efficacy, and how the use of ctDNA continues to evolve across the breast cancer space.
Read More
Fixed-Duration Venetoclax/Obinutuzumab Provides Robust PFS Benefit in Untreated CLL
July 29th 2022Othman Al-Sawaf, MD, discusses the 5-year follow-up data of the phase 3 CLL14 trial and emphasized the importance of fixed-duration treatments in high-risk patients with chronic lymphocytic leukemia.
Read More
Ibrutinib Plus Obinutuzumab Elicits Intriguing Survival Benefits in Relapsed/Refractory CLL
July 27th 2022Christine Ryan, MD, discussed the evaluation of safety and efficacy of ibrutinib plus obinutuzumab in patients with relapsed/refractory CLL in the trial and how the results could result in another treatment option for patients with relapsed/refractory CLL.
Read More
CHOP-Based Combinations Represent Evolving Standard of Care in Frontline Treatment of PTCL
July 19th 2022Neha Mehta-Shah, MD, MSCI, discusses frontline therapies in peripheral T-cell lymphoma, highlighting the current treatment landscape and the need to explore more treatment options in clinical trials.
Read More
Kim and Schwartz Break Down the Role of Radiation Segmentectomy With Y-90 in Early-Stage HCC
July 18th 2022Edward Kim, MD, and Myron E. Schwartz, MD, discuss the background and findings of the RASER study, the role of radiation segmentectomy, and its potential to be combined with immunotherapy.
Read More
Streamlined Genomic Testing Platforms Are Taking on A Bigger Role in Cancer Care
July 18th 2022Genetic testing has afforded oncologists with the opportunity to identify patients who may have a higher risk of developing cancer and identify actionable mutations to allow patients to receive targeted therapy and have their long-term treatment plan mapped out at diagnosis.
Read More
Ovarian Function Suppression Drives Chemotherapy Benefits in Premenopausal HR+/HER2- Breast Cancer
July 15th 2022Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.
Read More